Tobias Kroon
AstraZeneca R&D
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: December 08, 2023
Chronotherapy with a glucokinase activator profoundly improves metabolism in obese Zucker rats.
Journal: Science translational medicine
Published: October 26, 2022
Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH.
Journal: Frontiers in endocrinology
Published: May 31, 2022
BMP4 gene therapy enhances insulin sensitivity but not adipose tissue browning in obese mice.
Journal: Molecular metabolism
Published: October 30, 2019
PPARγ and PPARα synergize to induce robust browning of white fat in vivo.
Journal: Molecular metabolism
Published: October 28, 2019
In vivo liposomal delivery of PPARα/γ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects.
Journal: Theranostics
Published: May 10, 2019
Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: December 02, 2016
Dosing profile profoundly influences nicotinic acid's ability to improve metabolic control in rats.
Journal: Journal of lipid research
Published: February 18, 2015
Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions.
Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: July 05, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026